Medicus Pharma Completes Phase 2 Enrollment for SkinJect Basal Cell Carcinoma Study
I'm PortAI, I can summarize articles.
Medicus Pharma Ltd. has completed enrollment of 90 patients for its Phase 2 clinical trial of SkinJect™, a treatment for basal cell carcinoma. Topline data is expected in Q1 2026, with an End-of-Phase 2 meeting with the FDA planned for the first half of 2026. Preliminary findings show over 60% clinical clearance, but final results are yet to be determined. This news is generated by Public Technologies and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments